Results show that mpMRI and PI-RADSv2 score have a greater ability to detect prostate cancer progression after TRT compared with PSA.
Addition of external beam therapy doesn't improve 5-year progression-free survival in prostate cancet
Data from 21 observational studies showed an 8% increased risk of prostate cancer.
Medicine is making progress to refine patient care.
The approach can help identify suitable candidates for active surveillance, but false positives and cost effectiveness are concerns.
Ten-year mortality rates of prostate cancer are low, regardless of whether patients are treated with radiotherapy, surgery, or undergo only active surveillance.
Decreases in use of screening following USPSTF recommendations against routine PSA screening.
Large study challenges previous research linking the procedure to slightly higher chance of disease.
Urinary, bowel, sexual function, and quality of life among men with prostate cancer may vary depending on treatment type.
Clinicians now have tools for improving prostate cancer screening and risk stratification.
Researchers' results showed that the presence of a urinary catheter and recent antibiotic use were associated with increased odds of intra-operative bacteremia.
Study tested the combination in men with treatment-naïve prostate cancer and bone metastasis.
Findings among men with localized intermediate- and high-risk prostate cancer.
Between 2007 to 2013, the incidence of metastatic PCa increased by 7.1% annually.
Patients' pre-existing urinary problems influenced their perceptions of symptom relief after prostate cancer treatment.
Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer.
Men with 1 or 2 copies of the HSD3B1 (1245C) allele are more likely to experience disease progression.
The odds were 16% lower for men who underwent external beam radiotherapy/intensity modulated radiation therapy, however.
Greatest racial disparity found in Los Angeles, the least in Minneapolis.
Even black men with relatively few comorbidities had increased risks of upgrading or upstaging compared with non-black patients.
Early prostate cancer diagnosis rates fell, while cases of advanced prostate cancer remained stable.
Overall decision regret for 16.9% of patients; more regret for RP than radiotherapy component.
Survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both.
Men who used the medications prior to radical prostatectomy had 83% greater odds of Gleason 7-10 tumors compared with non-users.
Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.
Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.
An analysis of individual participant data from 15 prospective studies suggests a protective effect.
Prostate cancer was diagnosed in 19.5% of PDE5i users vs 22.7% of nonusers, a statistically insignificant difference.
Skeletal-related events occurred in 38% of patients with metastatic castration-resistant prostate cancer.
ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)